New Amsterdam Pharma Announces Appointment of Ian Somaiya As Chief Financial Officer
10/23/23, 1:42 PM
Location
netherlandsIndustry
therapeutics
biotechnology
health care
Position
chief financial officer
NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 -- NewAmsterdam Pharma Company N.V. , a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol , for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Ian Somaiya as Chief Financial Officer
Company Info
Location
netherlands
Additional Info
Founded in 2019, NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating obicetrapib as the preferred LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.